Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free CUR Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Neuralstem (CUR) Competitors

Neuralstem logo
Compare

CUR vs. FNCH, NKGN, ZIVO, SQZ, and SRNE

Should you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Finch Therapeutics Group (FNCH), NKGen Biotech (NKGN), ZIVO Bioscience (ZIVO), SQZ Biotechnologies (SQZ), and Sorrento Therapeutics (SRNE). These companies are all part of the "medical" sector.

How does Neuralstem compare to Finch Therapeutics Group?

Neuralstem (NASDAQ:CUR) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Neuralstem has higher revenue and earnings than Finch Therapeutics Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuralstem$260K15.10-$4.93MN/AN/A
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A

Neuralstem has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Finch Therapeutics Group has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Finch Therapeutics Group's return on equity of -69.14% beat Neuralstem's return on equity.

Company Net Margins Return on Equity Return on Assets
Neuralstem-39,417.64% -170.51% -110.16%
Finch Therapeutics Group N/A -69.14%-26.92%

38.3% of Neuralstem shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 5.4% of Neuralstem shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Neuralstem's average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.

Company Overall Sentiment
Neuralstem Neutral
Finch Therapeutics Group Neutral

Summary

Neuralstem and Finch Therapeutics Group tied by winning 4 of the 8 factors compared between the two stocks.

How does Neuralstem compare to NKGen Biotech?

Neuralstem (NASDAQ:CUR) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

In the previous week, Neuralstem's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company Overall Sentiment
Neuralstem Neutral
NKGen Biotech Neutral

38.3% of Neuralstem shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 5.4% of Neuralstem shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Neuralstem has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Neuralstem has higher revenue and earnings than NKGen Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuralstem$260K15.10-$4.93MN/AN/A
NKGen BiotechN/AN/A-$82.94M-$1.51N/A

NKGen Biotech has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. NKGen Biotech's return on equity of 0.00% beat Neuralstem's return on equity.

Company Net Margins Return on Equity Return on Assets
Neuralstem-39,417.64% -170.51% -110.16%
NKGen Biotech N/A N/A -479.36%

Summary

Neuralstem and NKGen Biotech tied by winning 4 of the 8 factors compared between the two stocks.

How does Neuralstem compare to ZIVO Bioscience?

Neuralstem (NASDAQ:CUR) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Neuralstem's average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company Overall Sentiment
Neuralstem Neutral
ZIVO Bioscience Neutral

38.3% of Neuralstem shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 5.4% of Neuralstem shares are held by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Neuralstem has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500.

Neuralstem has higher revenue and earnings than ZIVO Bioscience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuralstem$260K15.10-$4.93MN/AN/A
ZIVO Bioscience$15.85K1,073.09-$7.78M-$2.18N/A

ZIVO Bioscience has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. ZIVO Bioscience's return on equity of 0.00% beat Neuralstem's return on equity.

Company Net Margins Return on Equity Return on Assets
Neuralstem-39,417.64% -170.51% -110.16%
ZIVO Bioscience N/A N/A -2,240.92%

Summary

Neuralstem beats ZIVO Bioscience on 5 of the 9 factors compared between the two stocks.

How does Neuralstem compare to SQZ Biotechnologies?

SQZ Biotechnologies (NYSE:SQZ) and Neuralstem (NASDAQ:CUR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Neuralstem has lower revenue, but higher earnings than SQZ Biotechnologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A
Neuralstem$260K15.10-$4.93MN/AN/A

38.5% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by company insiders. Comparatively, 5.4% of Neuralstem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

SQZ Biotechnologies has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.

SQZ Biotechnologies has a net margin of -369.96% compared to Neuralstem's net margin of -39,417.64%. SQZ Biotechnologies' return on equity of -119.83% beat Neuralstem's return on equity.

Company Net Margins Return on Equity Return on Assets
SQZ Biotechnologies-369.96% -119.83% -59.90%
Neuralstem -39,417.64%-170.51%-110.16%

In the previous week, SQZ Biotechnologies' average media sentiment score of 0.00 equaled Neuralstem'saverage media sentiment score.

Company Overall Sentiment
SQZ Biotechnologies Neutral
Neuralstem Neutral

Summary

SQZ Biotechnologies beats Neuralstem on 7 of the 9 factors compared between the two stocks.

How does Neuralstem compare to Sorrento Therapeutics?

Sorrento Therapeutics (NASDAQ:SRNE) and Neuralstem (NASDAQ:CUR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Neuralstem has lower revenue, but higher earnings than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.43N/A
Neuralstem$260K15.10-$4.93MN/AN/A

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Neuralstem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sorrento Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.

Sorrento Therapeutics has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Sorrento Therapeutics' return on equity of 0.00% beat Neuralstem's return on equity.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
Neuralstem -39,417.64%-170.51%-110.16%

In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled Neuralstem'saverage media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
Neuralstem Neutral

Summary

Neuralstem beats Sorrento Therapeutics on 5 of the 9 factors compared between the two stocks.

Get Neuralstem News Delivered to You Automatically

Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CUR vs. The Competition

Export
MetricNeuralstemBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ Exchange
Market Cap$3.93M$329.01M$6.25B$11.77B
Dividend YieldN/AN/A2.74%5.26%
P/E RatioN/AN/A29.2527.07
Price / Sales15.10189.48504.6873.43
Price / CashN/A22.4443.3053.90
Price / Book0.284.739.676.69
Net Income-$4.93M-$132.96M$3.55B$332.64M

Neuralstem Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CUR
Neuralstem
N/A$1.87
-2.1%		N/AN/A$3.93M$260KN/A6
FNCH
Finch Therapeutics Group
N/A$7.66
+3.5%		N/AN/A$12.30MN/AN/A190
NKGN
NKGen Biotech
N/A$0.06
flat		N/AN/A$7.84MN/AN/AN/A
ZIVO
ZIVO Bioscience
N/A$1.20
+2.6%		N/AN/A$4.80M$15.85KN/A10
SQZ
SQZ Biotechnologies
N/A$0.02
-0.4%		N/AN/A$708K$18.16MN/A1,620

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CUR) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel